Suppr超能文献

局限性前列腺癌患者及其伴侣决策辅助工具的有效性、成本效益及实施:一项阶梯式楔形整群随机对照试验的研究方案

Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: study protocol of a stepped-wedge cluster randomised controlled trial.

作者信息

Al-Itejawi Hoda H M, van Uden-Kraan Cornelia F, van de Ven Peter M, Coupé Veerle M H, Vis André N, Nieuwenhuijzen Jakko A, van Moorselaar Jeroen A, Verdonck-de Leeuw Irma M

机构信息

Department of Urology, VU University Medical Center, Amsterdam, The Netherlands.

Department of Clinical, Neuro- and developmental Psychology, Faculty of Behavioral and Movement Sciences, Amsterdam Public Health research institute, VU University, Amsterdam, The Netherlands.

出版信息

BMJ Open. 2017 Sep 15;7(9):e015154. doi: 10.1136/bmjopen-2016-015154.

Abstract

INTRODUCTION

Patient decision aids (PDAs) have been developed to help patients make an informed choice for a treatment option. Despite proven benefits, structural implementation falls short of expectations. The present study aims to assess the effectiveness and cost-utility of the PDA among newly diagnosed patients with localised prostate cancer and their partners, alongside implementation of the PDA in routine care.

METHODS/ANALYSIS: A stepped-wedge cluster randomised trial will be conducted. The PDA will be sequentially implemented in 18 hospitals in the Netherlands, over a period of 24 months. Every 3 or 6 months, a new cluster of hospitals will switch from usual care to care including a PDA.The primary outcome measure is decisional conflict experienced by the patient. Secondary outcomes comprise the patient's quality of life, treatment preferences, role in the decision making, expectations of treatment, knowledge, need for supportive care and decision regret. Furthermore, societal cost-utility will be valued. Other outcome measures considered are the partner's treatment preferences, experienced participation to decision making, quality of life, communication between patient, partner and health care professional, and the effect of prostate cancer on the relationship, social contacts and their role as caregiver. Patients and partners receiving the PDA will also be asked about their satisfaction with the PDA.Baseline assessment takes place after the treatment choice and before the start of a treatment, with follow-up assessments at 3, 6 and 12 months following the end of treatment or the day after deciding on active surveillance. Outcome measures on implementation include the implementation rate (defined as the proportion of all eligible patients who will receive a PDA) and a questionnaire for health care professionals on determinants of implementing an innovation.

ETHICS AND DISSEMINATION

This study will be conducted in accordance with local laws and regulations of the Medical Ethics Committee of VU University Medical Center, Amsterdam, The Netherlands. The results from this stepped-wedge trial will be presented at scientific meetings and published in peer-reviewed journals.

TRIAL REGISTRATION

Nederlands Trial Register NTR TC5177, registration date: May 28 2015.Pre-results.

摘要

引言

患者决策辅助工具(PDA)已被开发出来,以帮助患者对治疗方案做出明智的选择。尽管已证实其益处,但在实际应用中仍未达到预期效果。本研究旨在评估PDA在新诊断的局限性前列腺癌患者及其伴侣中的有效性和成本效益,并将PDA应用于常规护理中。

方法/分析:将进行一项阶梯式楔形整群随机试验。PDA将在荷兰的18家医院中依次实施,为期24个月。每3或6个月,一组新的医院将从常规护理转变为包含PDA的护理。主要结局指标是患者经历的决策冲突。次要结局包括患者的生活质量、治疗偏好、在决策中的作用、对治疗的期望、知识水平、对支持性护理的需求以及决策后悔程度。此外,还将评估社会成本效益。其他考虑的结局指标包括伴侣的治疗偏好、参与决策的体验、生活质量、患者、伴侣与医护人员之间的沟通,以及前列腺癌对关系、社交联系及其作为照顾者角色的影响。接受PDA的患者和伴侣还将被问及他们对PDA的满意度。基线评估在治疗选择后、治疗开始前进行,治疗结束后或决定进行主动监测后的第3、6和12个月进行随访评估。实施方面的结局指标包括实施率(定义为所有符合条件的患者中接受PDA的比例)以及针对医护人员的关于实施创新决定因素的问卷。

伦理与传播

本研究将按照荷兰阿姆斯特丹VU大学医学中心医学伦理委员会的地方法规进行。这项阶梯式楔形试验的结果将在科学会议上展示,并发表在同行评审期刊上。

试验注册

荷兰试验注册中心NTR TC5177,注册日期:2015年5月28日。预结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a4b/5640129/6a37d97283d3/bmjopen-2016-015154f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验